Tilray Medical has launched its first commercial German-grown medical cannabis products from its Aphria RX facility under a newly issued cultivation license. The company received Germany’s first medical cannabis cultivation license under MedCanG on July 15, 2024, allowing them to cultivate and manufacture a broad range of medical cannabis products. The strains selected for cultivation at the indoor facility are derived from top-performing varieties popular with patients in Canada. This development strengthens Tilray’s position in German medical cannabis cultivation, production, and distribution.
Tilray Medical Launches its First Commercial “Grown in Germany” Medical Cannabis Products Under its Newly Expanded Cultivation License
